Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 26, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 351 shares |
| Price per Share | £16.6550 |
| Transaction Date | October 20, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details an initial notification of a share acquisition by Dr. S. Dexter, a PCA of Dr. P. J. T. Vallance (President, Pharmaceuticals R&D), resulting from the re-investment of dividends paid on October 13, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific insider-related transaction.
Key Facts for Investor Verification
- The transaction was an acquisition of 351 ordinary shares at £16.6550 per share.
- The purchase was executed on October 20, 2016, on the London Stock Exchange.
- The transaction was driven by the re-investment of dividends paid to shareholders on October 13, 2016.
- The buyer is Dr. S. Dexter, identified as a PCA of Dr. P. J. T. Vallance.
- This filing does not contain financial performance data for the company.